We had reported that the presence of the GFI1-36N protein was associated with an increased incidence of mutations in genes encoding epigenetic modifiers such as DNMT3a and could be therapeutically exploited in AML therapy (2, 15). This evidence concerns the gene GFI1 and acute myeloid leukemia.